Global Retinitis Pigmentosa Treatment Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 106059
- Pages: 115
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Retinitis Pigmentosa Treatment market in this environment.
In terms of revenue, this research report indicated that the global Retinitis Pigmentosa Treatment market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Retinitis Pigmentosa Treatment industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Astellas Pharma Inc. aims at producing XX K Units Retinitis Pigmentosa Treatment in 2020, with XX % production to take place in global market, Caladrius Biosciences, Inc. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Retinitis Pigmentosa Treatment Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Retinitis Pigmentosa Treatment Market
Astellas Pharma Inc.
Caladrius Biosciences, Inc.
Dompe Farmaceutici S.p.A.
Genable Technologies Limited
Genethon
GenSight Biologics S.A.
Grupo Ferrer Internacional, S.A.
ID Pharma Co., Ltd.
InFlectis BioScience
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
M's Science Corporation
Mimetogen Pharmaceuticals Inc.
Nanovector s.r.l.
Orphagen Pharmaceuticals, Inc.
...
Major Type of Retinitis Pigmentosa Treatment Covered in Prudent Markets report:
BNP-RP
Cenegermin
CPK-850
Cutamesine
FAB-111
Others
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Homecare
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Retinitis Pigmentosa Treatment Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 BNP-RP -Product Introduction and Major Manufacturers
1.1.2 Cenegermin -Product Introduction and Major Manufacturers
1.1.3 CPK-850 -Product Introduction and Major Manufacturers
1.1.4 Cutamesine -Product Introduction and Major Manufacturers
1.1.5 FAB-111 -Product Introduction and Major Manufacturers
1.1.6 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Retinitis Pigmentosa Treatment Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Retinitis Pigmentosa Treatment Market
3.1.1 Top Companies leading Retinitis Pigmentosa Treatment Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Retinitis Pigmentosa Treatment Market
3.2.1 Top Companies leading Retinitis Pigmentosa Treatment Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Retinitis Pigmentosa Treatment Market
3.3.1 Top Companies leading Retinitis Pigmentosa Treatment Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Retinitis Pigmentosa Treatment Market
3.4.1 Top Companies leading Retinitis Pigmentosa Treatment Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Retinitis Pigmentosa Treatment Market
3.5.1 Top Companies leading Retinitis Pigmentosa Treatment Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Retinitis Pigmentosa Treatment Market
3.6.1 Top Companies leading Retinitis Pigmentosa Treatment Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Retinitis Pigmentosa Treatment Market
3.7.1 Top Companies leading Retinitis Pigmentosa Treatment Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Retinitis Pigmentosa Treatment Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Retinitis Pigmentosa Treatment Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Retinitis Pigmentosa Treatment Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Retinitis Pigmentosa Treatment Sales and Growth Rate (2021-2027)
5.2 Global Retinitis Pigmentosa Treatment Sales Value and Growth Rate (2021-2027)
6 Retinitis Pigmentosa Treatment Competitive Analysis
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Company Profiles
6.1.2 Astellas Pharma Inc. Product Introduction
6.1.3 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Caladrius Biosciences, Inc.
6.2.1 Caladrius Biosciences, Inc. Company Profiles
6.2.2 Caladrius Biosciences, Inc. Product Introduction
6.2.3 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Dompe Farmaceutici S.p.A.
6.3.1 Dompe Farmaceutici S.p.A. Company Profiles
6.3.2 Dompe Farmaceutici S.p.A. Product Introduction
6.3.3 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Genable Technologies Limited
6.4.1 Genable Technologies Limited Company Profiles
6.4.2 Genable Technologies Limited Product Introduction
6.4.3 Genable Technologies Limited Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Genethon
6.5.1 Genethon Company Profiles
6.5.2 Genethon Product Introduction
6.5.3 Genethon Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 GenSight Biologics S.A.
6.6.1 GenSight Biologics S.A. Company Profiles
6.6.2 GenSight Biologics S.A. Product Introduction
6.6.3 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Grupo Ferrer Internacional, S.A.
6.7.1 Grupo Ferrer Internacional, S.A. Company Profiles
6.7.2 Grupo Ferrer Internacional, S.A. Product Introduction
6.7.3 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 ID Pharma Co., Ltd.
6.8.1 ID Pharma Co., Ltd. Company Profiles
6.8.2 ID Pharma Co., Ltd. Product Introduction
6.8.3 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 InFlectis BioScience
6.9.1 InFlectis BioScience Company Profiles
6.9.2 InFlectis BioScience Product Introduction
6.9.3 InFlectis BioScience Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 International Stem Cell Corporation
6.10.1 International Stem Cell Corporation Company Profiles
6.10.2 International Stem Cell Corporation Product Introduction
6.10.3 International Stem Cell Corporation Retinitis Pigmentosa Treatment Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Ionis Pharmaceuticals, Inc.
6.12 M's Science Corporation
6.13 Mimetogen Pharmaceuticals Inc.
6.14 Nanovector s.r.l.
6.15 Orphagen Pharmaceuticals, Inc.
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
